Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Alzamend Neuro, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −3 vs. Q2 2024
- Shares held
- 42.1K
- +8.07K (+23.7%) vs. Q2 2024Converted for a 1-for-10 split
- Total value
- $71.2K
- −$63.6K (−47.2%) vs. Q2 2024
- New holders
- 3
- 2 more added
- Sold out
- 6
- 2 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $3.26M |
| Q1 2026 | 13 | $723.1K |
| Q4 2025 | 13 | $447.2K |
| Q3 2025 | 11 | $351.3K |
| Q2 2025 | 7 | $6.36K |
| Q1 2025 | 11 | $59.9K |
| Q4 2024 | 17 | $131.7K |
| Q3 2024 | 12 | $71.2K |
| Q2 2024 | 16 | $150.5K |
| Q1 2024 | 13 | $386.8K |
| Q4 2023 | 16 | $334.7K |
| Q3 2023 | 27 | $1.49M |
| Q2 2023 | 24 | $3.13M |
| Q1 2023 | 26 | $2.64M |
| Q4 2022 | 33 | $3.98M |
| Q3 2022 | 17 | $9.41M |
| Q2 2022 | 21 | $2.70M |
| Q1 2022 | 22 | $4.01M |
| Q4 2021 | 20 | $1.66M |
| Q3 2021 | 17 | $1.99M |
| Q2 2021 | 11 | $2.58M |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Alzamend Neuro, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Susquehanna International Group, LLP | 16,601 | $28.1K | 0.00% | +16,601 | New |
| Truist Financial Corp | 15,498 | $26.2K | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Tower Research Capital LLC (TRC) | 4,167 | $7.04K | 0.00% | +3,649+704.8% | AddedConverted for a 1-for-10 split |
| BlackRock, Inc. | 3,973 | $6.71K | 0.00% | +3,973 | New |
| Wells Fargo & Company | 1,000 | $1.69K | 0.00% | +1,000 | New |
| CoreCap Advisors, LLC | 708 | $1.20K | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Bank of America Corp | 105 | $177 | 0.00% | +96+1,005.3% | AddedConverted for a 1-for-10 split |
| Harbor Investment Advisory, LLC | 20 | $34 | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Activest Wealth Management | 20 | $34 | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| City State Bank | 4 | $7 | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Morgan Stanley | 3 | $5 | 0.00% | −0−9.1% | ReducedConverted for a 1-for-10 split |
| Parallel Advisors, LLC | 3 | $5 | 0.00% | −0−9.1% | ReducedConverted for a 1-for-10 split |
| Vanguard Group Inc | 0 | $0 | 0.00% | −7,855−100.0% | Sold outConverted for a 1-for-10 split |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −5,240−100.0% | Sold outConverted for a 1-for-10 split |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −1,969−100.0% | Sold outConverted for a 1-for-10 split |
| RFG Advisory, LLC | 0 | $0 | 0.00% | −1,667−100.0% | Sold outConverted for a 1-for-10 split |
| UBS Group AG | 0 | $0 | 0.00% | −513−100.0% | Sold outConverted for a 1-for-10 split |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −7−100.0% | Sold outConverted for a 1-for-10 split |
| BlackRock Inc. | – | – | – | – | Not filed |